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Chronic exposure to haloperidol and olanzapine
leads to common and divergent shape changes in the
rat hippocampus in the absence of grey-matter
volume loss
W. R. Crum1†, F. Danckaers2†, T. Huysmans2, M.-C. Cotel3, S. Natesan3, M. M. Modo4, J. Sijbers1,
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1Department of Neuroimaging, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Neuroimaging Sciences, De
Crespigny Park, London, UK
2Department of Physics, iMinds-Vision Laboratory, University of Antwerp, Antwerp, Belgium
3Department of Psychosis Studies, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK
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Background. One of the most consistently reported brain abnormalities in schizophrenia (SCZ) is decreased volume and
shape deformation of the hippocampus. However, the potential contribution of chronic antipsychotic medication expos-
ure to these phenomena remains unclear.
Method. We examined the effect of chronic exposure (8 weeks) to clinically relevant doses of either haloperidol (HAL) or
olanzapine (OLZ) on adult rat hippocampal volume and shape using ex vivo structural MRI with the brain retained inside
the cranium to prevent distortions due to dissection, followed by tensor-based morphometry (TBM) and elastic surface-
based shape deformation analysis. The volume of the hippocampus was also measured post-mortem from brain tissue
sections in each group.
Results. Chronic exposure to either HAL or OLZ had no effect on the volume of the hippocampus, even at exploratory
thresholds, which was conﬁrmed post-mortem. In contrast, shape deformation analysis revealed that chronic HAL and
OLZ exposure lead to both common and divergent shape deformations (q = 0.05, FDR-corrected) in the rat hippocampus. In
particular, in thedorsalhippocampus,HALexposure led to inwardshapedeformation,whereasOLZexposure led tooutward
shapedeformation. Interestingly, outwardshapedeformations thatwere common tobothdrugsoccurred in theventralhippo-
campus. These effects remained signiﬁcant after controlling for hippocampal volume suggesting true shape changes.
Conclusions. Chronic exposure to eitherHALorOLZ leads to both common anddivergent effects on rat hippocampal shape
in the absence of volume change. The implications of these ﬁndings for the clinic are discussed.
Received 22 October 2015; Revised 23 June 2016; Accepted 23 June 2016
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Introduction
Large-scale magnetic resonance imaging (MRI) studies
of patients with schizophrenia (SCZ) commonly report
decreases in hippocampal volume with robust effect
sizes (van Erp et al. 2015). Advances in computational
neuroanatomical techniques have reﬁned this to in-
clude descriptions of progressive shape deformations
that also occur in the hippocampus of SCZ patients
(Csernansky et al. 1998, 2002; Wang et al. 2001;
Shenton et al. 2002; Zierhut et al. 2013; Mamah et al.
2016). However, brain differences detected by MRI
are inﬂuenced by multiple factors, some with poten-
tially opposing effects, including the duration of expos-
ure to antipsychotic medication (Lieberman et al. 2005;
Ho et al. 2011). Dissecting the effects of disease and
other moderating factors, such as medication exposure
in clinical MRI studies is therefore extremely difﬁcult.
Data from the ENIGMA Schizophrenia Working
Group (n = 2028 SCZ patients and n = 2540 controls) sug-
gests that decreases in hippocampal volume are posi-
tively associated with the proportion of unmedicated
SCZ patients (van Erp et al. 2015). This suggests that
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structural abnormalities of the hippocampus may be
more severe in untreated patients and potentially,
those volume deﬁcits may be ameliorated, at least par-
tially, by treatment with antipsychotic drugs (APD)
(Szeszko et al. 2003; Narr et al. 2004; van Erp et al.
2015). In the recent ENIGMA dataset, 11 of the study
sample sites included patients predominantly treated
with second-generation (atypical) antipsychotics (SGA)
(van Erp et al. 2015). Importantly, longitudinal MRI
studies, which have the advantage of controlling for
baseline changes prior to medication exposure,
report signiﬁcant decreases from baseline in either the
grey-matter volume, or the shape of the temporal lobe
and the hippocampus in SCZ patients treated with
ﬁrst-generation antipsychotics (FGA), but not SGA
(Lieberman et al. 2005; McClure et al. 2006, 2008, 2013;
Koolschijn et al. 2010). A more recent study replicated
the ﬁnding of reduced temporal lobe grey-matter vol-
ume, but this effect was independent of APD treatment
(Ho et al. 2011). In addition, higher doses of quetiapine
are associated with decreased hippocampal grey-matter
volume (Ebdrup et al. 2011). In parallel to volume stud-
ies, longitudinal analysis of shape deformations in the
hippocampus reveals that these are present in
ultra-high-risk individuals and persist following transi-
tion to psychosis (Dean et al. 2016). Furthermore, inward
shape deformation of the posterior hippocampus
appears to predict the degree of positive symptoms in
these patients (Dean et al. 2016). Longitudinal studies
have also attempted to examine the potential inﬂuence
of antipsychotics on hippocampal shape. Mamah et al.
(2012) report progressive hippocampal shape abnormal-
ities between SCZ patients treated with haloperidol
(HAL), compared to olanzapine (OLZ) (Mamah et al.
2012). Shape deformation of the CA1 region in SCZ
patients is also reported to predict the dose of APD
required to treat positive symptoms (Zierhut et al.
2013). Conversely, at least four longitudinal studies re-
port no signiﬁcant relationships between antipsychotic
use and hippocampal volume or shape (Arango et al.
2003; Velakoulis et al. 2006; Panenka et al. 2007;
McClure et al. 2013). However, the lack of longitudinal-
ly followed untreated patients as a control means it
remains unclear whether these outcomes are the effect
of illness progression, antipsychotic treatment or an
interaction between the two. Further, none of the
human studies have linked the imaging changes to
post-mortem ﬁndings and therefore the relationship
between imaging-related structural changes and post-
mortem ﬁndings remains unclear (Vernon et al.
2011). Thus, whilst exposure to APD have been linked
to both hippocampal volume and shape changes in
SCZ patients, the ﬁndings are clearly equivocal.
Pre-clinical studies incorporating rodent MRI have
previously been useful to address this issue, providing
evidence that chronic exposure to either HAL or OLZ
leads to alterations in brain volume (Vernon et al.
2011, 2012, 2014). To date, however, there has been
no investigation of the effect of chronic APD exposure
on shape metrics, although this is possible using ro-
dent MR images (Delgado y Palacios et al. 2011;
Wheeler et al. 2013). In the current study, we set out
to address this question by utilizing ex vivo MRI data
available from our prior study of the effects of chronic
exposure to APD on rat brain volume (Vernon et al.
2011). Speciﬁcally, we tested for the presence of hippo-
campal volume differences per voxel, using tensor-
based morphometry (TBM) in male rats exposed for
8 weeks to either HAL (2 mg/kg per day) or OLZ (10
mg/kg per day), compared to vehicle (VEH)-treated
controls. TBM is a sensitive and observer-independent
measure of brain atrophy, which is well suited to ro-
dent MRI studies where the grey- to white- matter
ratio is low (Lau et al. 2008; Lerch et al. 2008; Vernon
et al. 2014; Harrison et al. 2015). In parallel, we applied
a novel elastic surface-based shape analysis method to
search for deformations in hippocampal shape as a
function of chronic APD exposure. Based on our
prior observations that chronic exposure to either
HAL or OLZ did not lead to a decrease in hippocam-
pal volume, using manual segmentation analysis, we
hypothesized that the more sensitive TBM analysis
may potentially disprove this ﬁnding. In terms of
shape metrics, since the available clinical data are
equivocal, we made no speciﬁc a priori hypothesis.
Materials and method
Animals
This study used ex vivo MR images and brain tissue
sections collected from VEH- and APD-exposed ani-
mals, as previously reported (Vernon et al. 2011) (see
also Supplementary materials and methods). No new
animalswere generated for this study. Brieﬂy, a common
VEH (β-hydroxypropylcyclodextrin, 20% w/v, acidiﬁed
by ascorbic acid to pH 6; n = 8), HAL (2 mg/kg per
day; n = 8; Sigma-Aldrich, UK), or OLZ (10 mg/kg per
day; n = 8; Biophore Pharmaceuticals Ltd, India) were
administered to experimentally naive, 10-week-old
male Sprague–Dawley rats (Charles River, UK), using
subcutaneously implanted osmotic minipumps for a
total of 8 weeks (Vernon et al. 2011). Osmoticminipumps
(AlzetModel 2ML4, 28days;Alzet,USA)ﬁlledwithdrug
or VEH solutions were inserted subcutaneously on the
back ﬂank under isoﬂurane anaesthesia (5% induction,
1.5% maintenance) and replaced once after 28 days.
Animals were habituated for 7 days before experimental
procedures, which were carried out in accordance with
the Home Ofﬁce Animals (Scientiﬁc procedures) Act,
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United Kingdom, 1986 and European Union Directive
2010/63/EU.
MRI acquisition
Brainswere prepared for ex vivoMRimaging asprevious-
ly described (Vernon et al. 2011, 2014) (see also
Supplementary materials and methods). Brieﬂy, MR
image acquisition was performed using a 7 T horizontal
small bore magnet (Varian, USA) with custom-made
quadrature volume radiofrequency (RF) coil (43 mm
inner diameter, Rapid Biomedical GmbH, Germany)
connected to a console running VnmrJ acquisition soft-
ware (v. 2.3; Varian). A modiﬁed multiecho, multislice
spin-echopulse sequencewasused for imageacquisition,
with the following parameters: ﬁeld of view = 35 × 35
mm2; matrix = 192 × 192; repetition time = 4200 ms; echo
time = 10, 20, 30, 40, 50, 60, 70, 80 ms; 8 averages, 50 slices,
0.5 mmthick,with a totaldurationof 2 h30 minandan in
plane resolution of 187 μm.
Assessment of hippocampal volume using TBM
A mean image of the entire dataset (n = 24 scans) was
generated using rigid-body registration (6 d.f.) using
a population-based registration method based on
FSL-FLIRT (Jenkinson & Smith, 2001; Jenkinson et al.
2002; Crum et al. 2013). Using this mean image, the
external and internal borders of the left and right
hippocampus (dorsal and ventral regions, approxi-
mately to −1.92 to −6.84 mm from bregma based on
the rat stereotaxic atlas (Watson & Paxinos, 2007)
were manually deﬁned using the polygon tool in
ITK-SNAP (http://www.itksnap.org) (Yushkevich
et al. 2006) by an expert rater (A.C.V.) using previously
published criteria (Wolf et al. 2002; Vernon et al. 2011)
(Fig.1a, b). Segmentation performance was assessed
using intra-class correlation coefﬁcient with values
<0.95 rejected. This segmentation was used to create
a binary mask for implementation in the TBM pipeline
(Fig. 1c). Tensor-based morphometry was used to as-
sess anatomical differences related to APD treatment
in the hippocampus as previously described (Vernon
et al. 2014) (see also Supplementary materials and
methods). Using high-dimensional non-rigid ﬂuid
registration, the binary hippocampus mask deﬁned in
the template space was warped back onto individual
MR images using the inverse of the transformation
and used for subsequent shape analysis.
Assessment of hippocampal shape using elastic
surface-based shape deformation analysis
The shape analysis pipeline has been reported previ-
ously (Danckaers et al. 2014) and is depicted in
Fig. 2a. Changes in the shape and size of the
hippocampus may be described by computing the in-
ward and outward displacement vectors from the sur-
face of the structure (Delgado y Palacios et al. 2011;
Wheeler et al. 2013). First, a reference hippocampal sur-
face is registered to a target hippocampal surface, by
minimizing the geometric distance between those sur-
faces while maintaining correspondences. Here, the
binary hippocampus mask (reference) is warped to
match the population average image of all rats (target).
Fig. 2b shows the geometric error (Euclidean distance)
between the original surface and the registered surface,
calculated for every surface and the average error
projected on to the average surface. From this ﬁnal
nonlinear atlas, a surface representation of the hippo-
campus is generated. Due to the anisotropy resulting
from the 2D acquisition (in-slice v. axial resolution),
the resulting 3D hippocampal surfaces exhibit a stair-
like structure. Therefore, in order to obtain a more ac-
curate 3D surface while still interpolating the actual
slices, the surfaces were prepared by interpolating
the distance transform of adjacent slices over a regular
grid. The global rigid registration and an elasticity-
modulated registration are then iteratively repeated
(n = 60 iterations). During the iterations, the stiffness
gradually decreases, such that the surface will become
more elastic through the iterations. The ﬁrst step of sur-
face registration is the application of a rigid alignment.
To that end, in both hippocampal surfaces correspond-
ing points are identiﬁed, by casting a normal ray from
each vertex of the reference surface to the target sur-
face. When the normal of an intersection point is in
the same direction, within a tolerance of 60°, as the
normal of the point on the reference surface, that
point can be considered corresponding. This tolerance
is based on the dot product between the normal of the
source vertex and the intersection of this normal with
the target surface. If this dot product >0.5, those points
are considered as corresponding points. Another re-
striction for corresponding points is that the normal
may not intersect the surface multiple times before
reaching the corresponding point. Once corresponding
point sets are obtained, they are used to rigidly align
the surfaces in a least squares sense using singular
value decomposition.
In the elastic part of the registration, the vertices are
allowed to translate separately, while motion is
restricted by a stiffness parameter, which regulates
the strength of the connection with the neighbouring
vertices and which decreases during the iterations.
The stiffness parameter is β in the pipeline (Fig. 2a)
and regulates how stiff or elastic the surface can be-
have. When this parameter is high, the neighbouring
vertices of a translated vertex are forced to move (par-
tially) along. In contrast, when this parameter is low,
the surface is more elastic and the connection between
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neighbouring vertices is lower, such that these may
move more freely. By applying weights to each vertex,
the importance of this vertex can be set. If no corre-
sponding point for a vertex of the source mesh can
be found, its weight is set to zero. In that case, this ver-
tex simply translates along with its neighbouring verti-
ces. When all surfaces are registered by the same
reference surface, each vertex has the same anatomical
location on each hippocampal surface.
Post-mortem tissue handling and Cavalieri probe
analysis of hippocampal volume
After MRI acquisition, brains were removed from the
skull and processed for Nissl staining as previously
described (Vernon et al. 2011) (see also Supplementary
materials and methods). A single observer (M.C.C.)
blinded to experimental group by coding measured
the volume of the hippocampus using the Cavalieri
Fig. 1. (a) Anatomical criteria for creation of the binary mask for tensor-based morphometry (TBM) and shape analysis of the
rat hippocampus using a mean MR image of the entire dataset (n = 24 scans). The orientation of the displayed scans is in the
coronal plane. (b) Three-dimensional rendering of the binary mask of the rat hippocampus. (c) Processing pipeline for
automated TBM analysis.
Fig. 2. (a). Image processing pipeline for elastic surface-based shape deformation analysis. (b) The geometric error (Euclidean
distance) between the original surface and the registered surface. This error is calculated for every surface and the average
error is projected on the average surface and displayed with a colour map.
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estimator (Gundersen & Jensen, 1987) as described else-
where (Vernon et al. 2011) (see also Supplementary
materials and methods).
Statistical analysis
Voxel-wise analyses of local volume changes for group
differences were computed using a one-way ANOVA
followed by voxel-wise t tests to compare VEH to
each antipsychotic drug (VEH v. HAL; VEH v. OLZ),
as well as each antipsychotic to the other (HAL v.
OLZ) (Vernon et al. 2014). Shape changes were ana-
lysed per vertex by comparing the vector lengths and
direction, performing a covariance calculation using
non-parametric permutation tests based on Hoteling’s
T2 statistics. For both volume and shape analysis, mul-
tiple comparisons were controlled for using the FDR at
q = 0.05 (Genovese et al. 2002). Due to the small sample
size in the current study, the data were also analysed at
an exploratory threshold of p < 0.05 uncorrected for mul-
tiple comparisons. Post-mortem volume data were ana-
lysed using one-way ANOVA with Bonferroni post-hoc
test using SPSS v. 22.0 software (IBM Corp., USA).
Ethical standards
The authors assert that all procedures contributing to
this work comply with the ethical standards of the rele-
vant national and institutional guides on the care and
use of laboratory animals.
Results
Chronic APD exposure has no signiﬁcant effect on
hippocampal volume in naive rats
The TBM analysis revealed no signiﬁcant effects (FDR,
q = 0.05) of chronic exposure (8 weeks) to either HAL or
OLZ on hippocampal volume, in either the left or right
brain hemisphere (Supplementary Fig. S1A, B). This
replicates our previous null ﬁndings using manual seg-
mentation (Vernon et al. 2011). As the sample size was
small, which may compromise our ability to detect
subtle changes, we carried out an additional explora-
tory analysis (p < 0.05 uncorrected; (Vernon et al.
2014). However, even at this exploratory threshold
we could not detect any clusters of contracted or
expanded voxels in our hippocampal region of interest
(data not shown).
Impact of chronic APD exposure on hippocampal
shape deformation
The results of the shape analysis are shown in Fig. 3a–c.
It is clear from the data that there are both net outward
and inward vertex displacements in hippocampal
shape following chronic exposure to either anti-
psychotic compared to VEH-treated animals. Chronic
HAL exposure resulted in signiﬁcant (q < 0.05,
FDR-corrected; Fig. 3a) inward displacement in the
dorsal hippocampus compared to VEH-treated rats.
These displacements are bilateral, but appear more
pronounced in the left hemisphere of the brain. These
inward displacements correspond approximately to
the cornu ammonis 1 (CA) and sub-ﬁeld, extending
through the oriens, pyramidal and radiatum layers to
touch the CA3 sub-ﬁeld. Additional signiﬁcant, bilat-
eral inward deformations were also found in the CA3
sub-ﬁeld in the ventral hippocampus. In contrast, sign-
iﬁcant outward deformations were observed in both
hemispheres of the ventral hippocampus. These are
again bilateral, but predominate in the right hemi-
sphere and correspond approximately to the CA1
and CA2 sub-ﬁelds.
Chronic OLZ exposure also led to signiﬁcant (q <
0.05; FDR-corrected; Fig. 3b) deformations in the dorsal
and ventral hippocampus compared to VEH-exposed
rats. Although these deformations overlap topograph-
ically with those observed in HAL-exposed animals,
speciﬁcally to the left dorsal CA1 sub-ﬁeld and right
ventral CA1 and CA2 sub-ﬁelds, they are less wide-
spread (Fig. 3a, b). Furthermore, the dorsal CA1 defor-
mations in OLZ-exposed animals are in the opposite
direction to those in HAL-exposed animals, moving
outward, rather than inward, relative to VEH controls
(Fig. 3a, b). When directly comparing shape differences
between HAL- and OLZ-exposed animals, this effect
shows up as a subtle, but signiﬁcant difference be-
tween the two APD (Fig. 3c). Interestingly however,
in the ventral aspect of the hippocampus in
OLZ-exposed rats, there is vertex displacement that
overlaps both in terms of topography and direction
of change with those observed in HAL-exposed ani-
mals, although these did not survive multiple compar-
isons correction (Fig. 3b).
The lack of TBM changes strongly suggests the vol-
ume of the hippocampus is not altered across treat-
ment groups and that these deformations represent
true shape changes. However, this can also be tested
directly using volume normalization in order to visual-
ize the pure shape differences. In Fig. 4, the volume of
the hippocampal surfaces is normalized such that each
hippocampus has a size of 1. When comparing the data
before and after volume normalization, the results are
identical, consistent with the lack of volume change
detected by TBM or manual segmentation. These
data strongly suggest that we are detecting true
shape changes in the hippocampus following chronic
exposure to APD. The presence of both inward and
outward shape deformations is therefore also consist-
ent with the failure to ﬁnd signiﬁcant differences in
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volume, either by TBM or manual segmentation, since
the net hippocampal volume change may be very close
to zero.
Conﬁrmation of the absence of hippocampal volume
changes post-mortem
Post-mortem volume analysis using the Cavalieri probe
revealed no signiﬁcant overall differences in the
total volume (dorsal + ventral) of the left hippocampus
between treatment groups (F2,21 = 0.1.75, p > 0.05; Fig. 5
and Supplementary Table S1).
Discussion
Contrary to our hypothesis, TBM analysis conﬁrmed
that chronic exposure (8 weeks) to either HAL or
Fig. 4. Normalization of hippocampal volume does not alter the pattern of signiﬁcant voxels identiﬁed by elastic shape
deformation analysis, suggesting true shape changes. Data shown are size and shape and shape only (volume normalized
to 1) for (a) vehicle v. haloperidol; (b) vehicle v. olanzapine and (c) haloperidol v. olanzapine.
Fig. 3. Elastic shape deformation analysis reveals common and divergent effects of chronic haloperidol and olanzapine
exposure on hippocampal shape metrics. Data shown are the mean inward and outward displacement vectors (mm), shown
both at an exploratory threshold of p < 0.05 uncorrected for multiple comparisons and q = 0.05 FDR-corrected, to illustrate
signiﬁcant differences in hippocampal shape metrics between (a) vehicle and haloperidol; (b) vehicle and olanzapine and (c)
haloperidol and olanzapine exposed rats. Directionality of statistically signiﬁcant hippocampal shape deformations, either
inward (blue) or outward (red), may be found by comparing the p value maps with the mean displacement vector maps in
each treatment group comparison. A, Anterior; P, posterior; S, superior; I, inferior; L, left; R, right.
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OLZ, at clinically relevant doses, does not lead to
changes in the volume of the rat hippocampus. In con-
trast, the results of the shape analysis reveal that chron-
ic exposure to either HAL or OLZ results in common
shape changes both in terms of their topography and
direction, particularly in the ventral hippocampus.
However, the data also provide preliminary evidence
for minor divergent shape changes following exposure
to these two different antipsychotics, particularly in the
CA1 sub-ﬁeld of the rat dorsal hippocampus. In this re-
gion, while the drug-induced shape changes overlap
topographically, HAL exposure leads to inward defor-
mations, whilst OLZ leads to outward deformations.
Furthermore, hippocampal shape changes appear
more widespread following HAL treatment, particu-
larly again in the dorsal hippocampus. These data
raise new questions about our interpretation of clinical
MRI data and how antipsychotics might impact hippo-
campal structure in SCZ patients.
In the largest cross-sectional MR imaging dataset
available comparing healthy controls and SCZ
patients, including both medicated and un-medicated
individuals (ENIGMA; van Erp et al. 2015), the volume
of the hippocampus in SCZ patients was signiﬁcantly
reduced (Cohen’s d =−0.46). This reduction was more
pronounced in patients who were not medicated (van
Erp et al. 2015). Interestingly, the majority of medicated
patients were treated with SGA. Although the FGA/
SGA nomenclature is a poorly deﬁned and heteroge-
neous construct (Leucht et al. 2009), prior studies
suggest there may be distinct effects of different
APD on brain volume. For example cortical volume
(Lieberman et al. 2005; Ansell et al. 2015) and cortical
thickness (van Haren et al. 2011) are reported to be
less apparent in SCZ patients treated with SGA, in-
cluding OLZ. A recent meta-analysis of longitudinal
structural MRI studies in medicated SCZ patients
also suggests SGA have less impact on brain volume,
compared to FGA, including HAL (Vita et al. 2015).
In contrast, primate (Dorph-Petersen et al. 2005) and
rodent (Vernon et al. 2011) pre-clinical studies have
failed to ﬁnd signiﬁcant differences between the effects
of HAL and OLZ on brain volume following chronic
exposure, including no effect on hippocampal volume,
using manual segmentation (Vernon et al. 2011). The
results of the current study using operator-
independent voxel-wise TBM analysis, which has
greater sensitivity for subtle anatomical changes
conﬁrm our prior in vivo data. Furthermore, we corrob-
orate the TBM analysis post-mortem using unbiased
stereology analysis of hippocampal volume from
Nissl stained tissue sections. The lack of hippocampal
volume change following APD exposure may reﬂect
the fact that these are naive animals, which do not rep-
licate pathological conditions relevant to SCZ.
Alternatively, since the hippocampal shape deforma-
tions are both inward and outward, the net volume
change may be close to zero. These data are, however,
consistent with the majority of hippocampal volume
MRI studies in patients with SCZ which ﬁnd no rela-
tionship between antipsychotic dose and hippocampal
volume (Marsh et al. 1994; Whitworth et al. 1998;
Stefanis et al. 1999; Altshuler et al. 2000; Gur et al.
2000; Arango et al. 2003; Szeszko et al. 2003; Narr
et al. 2004; Lieberman et al. 2005; Velakoulis et al.
2006; Panenka et al. 2007; Koolschijn et al. 2010; Ho
et al. 2011).
Importantly, shape analysis complements volumetric
analysis and can identify subtle regional abnormalities
in brain structures in the absence of overall volumetric
changes (Csernansky et al. 1998; Csernansky et al.
2002). The current study therefore provides the ﬁrst pre-
clinical evidence that chronic exposure to HAL or OLZ
leads to common, but also distinct effects on hippocam-
pal shape. Speciﬁcally, chronic treatment with both
drugs led to topographically overlapping shape defor-
mations, which were clearly more extensive in HAL
than OLZ treated animals. Interestingly, in the dorsal
CA1 sub-ﬁeld, HAL exposure led to inward deform-
ation, while OLZ promoted outward deformation. In
contrast, both HAL and OLZ had similar effects in the
ventral hippocampus, promoting predominantly out-
ward deformations, although it is notable these did
not survive FDR correction in OLZ-exposed rats.
These data are partly consistent with ﬁndings from a
longitudinal MRI study of ﬁrst-episode SCZ patients
randomized to either HAL or OLZ, which suggested
that OLZ treatment was associated with a signiﬁcantly
lower percentage of ‘large magnitude negative surface
vertex slopes’ as compared to HAL treatment, when
patients were followed up to 104 weeks (Mamah et al.
Fig. 5. Post-mortem conﬁrmation of the lack of
hippocampal volume changes in rats chronically exposed to
either haloperidol or olanzapine using the Cavalieri probe.
Data shown are individual hippocampal volume (scatter
plot with mean) in vehicle (V), haloperidol (H) and
olanzapine (O) treated rats.
Antipsychotic medication and hippocampal shape change 7
2012). Notably however, other studies on the same data-
set found no effect of antipsychotic exposure at any
follow-up time point (McClure et al. 2006, 2008, 2013).
This may be explained by the differential shape analysis
methods employed in these studies, which could inﬂu-
ence the results (Mamah et al. 2016). Our preclinical data
suggest the dorsal hippocampus is a potential locus of
differential shape changes,whilst the ventral hippocam-
pus shows common shape changes following chronic
treatment with either HAL or OLZ in the naive rat
brain. Although preliminary, these data suggest a test-
able hypothesis for future studies with a larger sample
size to conﬁrm these data. This could also provide a
dataset for the controlled testing of the effects of differ-
ent shape analysis methodology, which may also be
beneﬁcial to the ﬁeld.
It is conceivable however, that the observed hippo-
campal shape changes may reﬂect volume changes in
adjacent brain regions, which cause an alteration in
hippocampal shape rather than volume. In our prior
work, we have shown that chronic antipsychotic ex-
posure decreases total cortical volume, but primarily
in the cingulate and somatosensory cortex (Vernon
et al. 2011, 2014). Chronic HAL exposure also leads to
striatal enlargement (Vernon et al. 2012). However, as
yet we do not have information regarding the effects
of chronic antipsychotic exposure on the shape or vol-
ume of other sub-cortical nuclei in close proximity to
the hippocampus, in particular, the thalamus. Further
studies using both TBM and shape analysis are
required to assess the potential inﬂuence of alterations
in volume or shape metrics in these structures on the
present ﬁndings in the hippocampus.
What might be the cellular origin of these APD-
induced hippocampal shape changes? Rigorous post-
mortem studies in macaque monkeys using clinically
comparable plasma levels, chronic antipsychotic treat-
ment, and unbiased stereology reported a signiﬁcant
20% decrease in the total number of S100β + astrocytes
albeit in the grey matter of the left parietal lobe, but no
change in neuronal number (Konopaske et al. 2008).
These provide immediately testable hypothesis for fu-
ture studies in the rat brain. Using post-mortem brain
tissue from the same animals from which the current
imaging data were generated, we have recently
reported that chronic HAL and OLZ exposure resulted
in highly signiﬁcant increases in the density of amoeb-
oid Iba1+ microglia in both the dorsal and ventral rat
hippocampus (Cotel et al. 2015). These effects on micro-
glia thus overlap topographically with the areas of
shape change in the rat hippocampus after chronic
HAL or OLZ exposure. Furthermore, both HAL and
OLZ have been previously reported to impact on
growth factors, particularly nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF) and
ﬁbroblast growth factor (FGF) (Pillai & Mahadik,
2006; Pillai et al. 2006). Moreover, oxidative stress in
the hippocampus has been reported following HAL,
but not OLZ treatment (Reinke et al. 2004).
Altogether, changes in these parameters could lead to
alterations in axon sprouting, ﬁbre reorganization,
myelin formation; neurogenesis, dendritic spine
morphology (Uranova et al. 1991) and angiogenesis,
all of which reﬂect potential contributors to the
observed hippocampal shape changes.
The clinical impact of these APD-induced shape
changes also remains unclear. Indeed, it is challenging
to label the directionality of our ﬁndings as ‘beneﬁcial’
or ‘harmful’ (Lewis, 2011). The human (or primate)
hippocampus may be functionally divided along its
anterioposterior axis into an anterior part, which is
involved in emotional processing and a posterior
part, which is predominantly involved in memory
function. In contrast, the rat hippocampus is orientated
along a dorsal-ventral axis, divided into the dorsal and
ventral sections, which are also functionally disso-
ciated (Moser & Moser, 1998; Fanselow & Dong,
2010). Speciﬁcally, the dorsal part of the rat hippocam-
pus contributes to cognitive functions, including spa-
tial learning and memory and is therefore analogous
to the human (or primate) posterior hippocampus
(Bannerman et al. 2004; McHugh et al. 2004). In con-
trast, the rat ventral hippocampus is involved in the
regulation of stress, anxiety and emotional memory
and is therefore analogous to the human (or primate)
anterior hippocampus (Barkus et al. 2010). As such,
both divisions of the hippocampus show differential
connectivity patterns. For example, memory function
is critically dependent upon connections between the
dorsal hippocampus and retrosplenial granular and
anterior cingulate cortices (ACC) (Fanselow & Dong,
2010). Patients with SCZ exhibit non-speciﬁc hyper-
activity of the left anterior hippocampus during a long-
term memory task, which is related to positive symp-
tom severity (Zierhut et al. 2010). Furthermore, ultra-
high risk and ﬁrst-episode psychosis individuals dem-
onstrate increased cerebral blood ﬂow speciﬁcally in
the anterior CA1 sub-ﬁeld of the hippocampus,
which correlates with atrophy of this region and pre-
dicts transition to psychosis (Schobel et al. 2009;
Schobel et al. 2013). Several studies have also identiﬁed
inward shape deformations in the anterior and poster-
ior aspects of the human hippocampus, which are cor-
related with the extent of positive symptoms in SCZ
patients (Csernansky et al. 2002; Small et al. 2011;
Zierhut et al. 2013; Dean et al. 2016; Mamah et al.
2016). Inward shape deformations of the anterior and
posterior CA1 sub-ﬁeld also predicts daily antipsychot-
ic drug dosage in SCZ patients (Zierhut et al. 2013;
Dean et al. 2016). Shape deformations of the CA1 sub-ﬁ
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eld, may therefore be the consequence of a disease-
speciﬁc hyperactive hippocampal state, leading to ele-
vated glutamate levels, downstream atrophy and dis-
ruption of CA1 functional connectivity, resulting in
the symptomatology of SCZ (Schobel et al. 2009;
Schobel et al. 2013; Zierhut et al. 2013). Speculatively,
the common outward shape deformations we observe
in the ventral hippocampus, the rat homologue of the
human anterior hippocampus following chronic expos-
ure to either HAL or OLZ, may reﬂect a structural con-
sequence of alterations in hippocampus/CA1 activity
or functional connectivity, which may be related to
the therapeutic effects of these medications on positive
symptoms, through correction of aberrant brain activ-
ity patterns. In other words, a beneﬁcial effect related
to the therapeutic action of the drug.
In contrast, these APD-induced hippocampal shape
deformations may be related to adverse motor and cog-
nitive side-effects of APD. Notably, we previously
observed common effects of both HAL and OLZ to de-
crease ACC volume, which were more apparent in
HAL-treated rats (Vernon et al. 2014). These data may
suggest a link between hippocampal shape deforma-
tions, ACC volume and functional connectivity of
these structures following chronic antipsychotic drug
treatment, which requires exploration. Although recent
studies have begun to examine the complex network
effects of antipsychotics on brain functional connectivity
(Gass et al. 2013;Wheeler et al. 2014), no study has to date
linked these to morphometric changes or behavioural
outcomes following chronic dosing. Of possible rele-
vance to this study however, Gass et al. (2013) reported
decreased functional connectivity between the substan-
tia nigra and the CA2 region of the dorsal hippocampus
in rats following acute HAL challenge (Gass et al. 2013).
Further studies are required combining functional and
structural MR imaging to address whether alterations
in brain activity are related to structural remodelling fol-
lowing chronic APD exposure. Importantly, there is a
paucity of preclinical studies examining the relationship
between chronic APD exposure using clinically relevant
dosing and the cognitive or emotional functions ascribed
to the dorsal andventral aspects of the rodent hippocam-
pus. Although prior studies have not typically used
mini-pump delivery methods, acute and chronic treat-
ment with various APD leads to impairment in Morris
water-maze tasks of spatial learning but not other
maze tasks, such as the elevated plus maze or radial
arm maze (Skarsfeldt, 1996; Didriksen et al. 2006; Terry
&Mahadik, 2007; Hutchings et al. 2013). Further studies
are therefore required to understand the links between
dorsal and ventral hippocampus shape deformations,
cognitive and emotional behaviour, particularly any dif-
ferences, or indeed, similarities, following exposure to
HAL or OLZ.
It should be noted, however, that we examined male
rats only. This is relevant, since a prior study reported
a signiﬁcant decrease in hippocampal volume, follow-
ing chronic OLZ exposure in female SD rats (Barr et al.
2013). Interestingly, this decrease was related to meta-
bolic side effects of chronic OLZ exposure, in this case,
impaired glucose tolerance and increased peripheral
adiposity (Barr et al. 2013). Notably, we have previous-
ly reported that the OLZ-exposed animals used in this
study have lower hepatic levels of Insulin receptor sub-
strate 2 (IRS2), indicative of impaired insulin signalling
and gluco-metabolic abnormalities (Mondelli et al.
2013). However, these animals did not show weight
gain or increased adiposity as compared to VEH con-
trols (Mondelli et al. 2013). In contrast, the HAL-
exposed rats showed increase adiposity, in the absence
of weight gain and no change in hepatic IRS2 protein
levels (Mondelli et al. 2013). These data suggest that
different molecular pathways mediate the disturbances
of glucose homeostasis induced by HAL and OLZ, at
least in male rats; nonetheless, metabolic abnormalities
were clearly present in both antipsychotic exposed
groups. However, female rats produce more consistent
and perhaps larger, metabolic changes than males in
response to antipsychotic exposure (Boyda et al. 2010)
which may contribute to reduced hippocampal volume
(Barr et al. 2013). However, the study by Barr and col-
leagues also used different dosing methods (daily in-
jection v. osmotic minipumps in the current study),
which may affect the data by virtue of differential
pharmacokinetics (Kapur et al. 2003). Nevertheless,
investigations into potential sex differences in the
effects of APD on brain structure and function, particu-
larly in relation to peripheral metabolic side effects of
these drugs are clearly required.
Importantly, the current experiments were con-
ducted in healthy rats, free from pathology, in order
to deﬁne the effects of chronic antipsychotic exposure
on shape and volume metrics in a controlled fashion.
Ultimately, however, to begin to establish whether
these drug-induced hippocampal shape changes are ei-
ther beneﬁcial or harmful, will require repetition of
these experiments in rat models that model relevant
aspects of SCZ pathology. Speciﬁcally, these could in-
clude MR-detectable increases in hippocampal activity
and associated decreases in the volume of the hippo-
campus such as those observed following either pre-
natal exposure to maternal infection (Piontkewitz
et al. 2011) or chronic N-methyl-D-aspartate receptor
antagonism (Schobel et al. 2013; Barnes et al. 2015).
This may well reveal important differences, including
any drug x disease interactions and bring us closer to
a clearer vision of the potential clinical implications
of these ﬁndings. Further caveats regarding the
interpretation of our ﬁndings should be also be
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acknowledged. The use of hippocampal surface mod-
els relies on manual tracing, and systematic bias in de-
lineating this region might adversely affect its
reliability. However, the reliability of the segmentation
method has been shown to be high (Wolf et al. 2002).
Although the tracings were performed blinded to treat-
ment group, any differences in image contrast between
VEH and antipsychotic-treated rats could also poten-
tially affect the results. Nevertheless, we have not
detected signiﬁcant changes in T2 signal intensity in
other brain regions that displayed volume changes
after chronic APD treatment (Vernon et al. 2011). The
resolution of our MR images is relatively low and the
original images were not isotropic. It is therefore pos-
sible that partial volume effects or imperfections in
image registration may be driving the observed effects
of HAL and OLZ on hippocampal shape. Although the
registration error between the source and target images
was low (see Fig. 2b), it will be important to conﬁrm
our observations by collecting higher resolution ex
vivo MR images with isotropic voxels from VEH
and antipsychotic-treated rats. The sample size is
small (n = 8 per group) and our ﬁndings thus require
conﬁrmation in a larger sample size. Notably, we
have however replicated the effects of HAL on cerebral
morphometry observed in these same animals (Vernon
et al. 2011) in a larger sample size of n = 12 per group
(Vernon et al. 2012). We tested only one dose of each
antipsychotic drug, which although within the range
of striatal D2 receptor occupancy similar to levels
obtained in clinical settings (Kapur et al. 2003) a full
dose response study may be beneﬁcial.
In conclusion, we show for the ﬁrst time that chronic
treatment of naive adult rats with either HAL or OLZ
lead to changes in hippocampal shape metrics, in the
absence of volume changes. Strikingly, the effects of
both drugs were relatively common, particularly in
the ventral hippocampus. Nevertheless, our data also
suggest preliminary evidence for differential shape
changes following HAL or OLZ exposure in the dorsal
hippocampus, which require conﬁrmation in a larger
sample size. The effects were more profound with
HAL, as compared to OLZ, consistent with recent clin-
ical observations. It is however, important to stress that
these data were collected in normal rats, which does
not reﬂect the innate pathology of SCZ. Furthermore,
because the cellular basis and functional consequences
of these effects remain unknown, one should be cau-
tious in drawing clinical inferences. Nonetheless, our
studies provide a clear rationale for future experiments
to explicitly examine the relationships between
changes in hippocampal shape metrics and how
these relate to the efﬁcacy of APD as well as morpho-
logical, cognitive and metabolic side effects of chronic
APD treatment.
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